0000000000587787

AUTHOR

Michela Ortoncelli

showing 3 related works from this author

Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

2021

Abstract Background Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID‐19) pandemic. Methods A national registry, named DA‐COVID‐19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID‐19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID‐19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severi…

Registrie0301 basic medicineDermatitisSystemic therapy0302 clinical medicinePandemicImmunology and AllergyMedicineRegistriesatopic dermatitis; COVID; SARS‐ CoVCOVIDtreatmentatopic dermatitisatopic dermatitis; COVID; SARS-CoVSARS-CoVAtopic dermatitisDupilumabSARS‐ CoVItalyOriginal ArticleSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanatopic dermatitiAdultmedicine.medical_specialtyTeledermatologyCOVID; SARS‐CoV; atopic dermatitis treatmentCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyCOVID; SARS‐CoV; atopic dermatitis; Adult; Communicable Disease Control; Humans; Italy; Pandemics; Registries; SARS-CoV-2; COVID-19; Dermatitis AtopicAtopicDermatitis Atopic03 medical and health sciencesSettore MED/35Disease severityInternal medicineatopic dermatitis treatmentHumansPandemicsPandemicbusiness.industrySARS-CoV-2SARS‐CoVCOVID-19medicine.disease030104 developmental biology030228 respiratory systemCommunicable Disease Controlatopic dermatitis; COVID; SARS-CoV; Adult; Communicable Disease Control; Humans; Italy; Pandemics; Registries; SARS-CoV-2; COVID-19; Dermatitis Atopicatopic dermatitis COVID SARS-CoVbusiness
researchProduct

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudin…

2021

AbstractBackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised…

Response ratemedicine.medical_specialtyCost per responderBiologicCostIxekizumabLongitudinal StudieContext (language use)Secukinumab.Severity of Illness IndexAntibodiesIndirect costsSettore MED/35Quality of lifeInternal medicinePsoriasisUstekinumabMonoclonalAdalimumab; Ixekizumab; Antibodies Monoclonal; Longitudinal Studies; Quality of Life; Psoriasis; Treatment Outcome; Severity of Illness Index; Italy; Humans; Biological Therapy; Ustekinumab; Secukinumab; Response rate; Real-world; Ixekizumab; Cost per responder; BiologicmedicineAdalimumabHumansPsoriasisLongitudinal Studieshealth care economics and organizationsSecukinumabPsoriasiAdalimumab; Biologic; Cost per responder; Costs; Ixekizumab; Real-world; Response rate; Secukinumab; Ustekinumab; Antibodies Monoclonal; Biological Therapy; Humans; Italy; Longitudinal Studies; Severity of Illness Index; Treatment Outcome; Psoriasis; Quality of Lifebusiness.industryHealth PolicyResearchAdalimumabAntibodies Monoclonalmedicine.diseaseCostsBiological TherapyIxekizumabTreatment OutcomeReal-worldItalyQuality of LifeSecukinumabUstekinumabPublic aspects of medicineRA1-1270Settore MED/35 - MALATTIE CUTANEE E VENEREEbusinessHumanmedicine.drugBMC Health Services Research
researchProduct

Additional file 1 of A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA obs…

2021

Additional file 1.

Data_FILES
researchProduct